An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

Exclusion criteria

• ✕. Subjects with SAE in the "Exploratory clinical Study Evaluating AAV2-RPE65 gene therapy agent (LX101) in patients with congenital Amaurosis (LCA)
• ✕. pre-existing eye conditions (such as glaucoma, cornea, or severe lens opacity) that the investigator determines may interfere with planned surgery or with interpretation of the study endpoint;
• ✕. Screening subjects who had undergone any internal eye surgery in the six months prior to the visit;
• ✕. Inability or unwillingness to meet the requirements of the study;